We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Back to the drawing board for Lykos' MDMA therapy.
- Authors
Knopf, Alison
- Abstract
The Food and Drug Administration (FDA) did not accept the application of Lykos Therapeutics for MDMA as a treatment for post‐traumatic stress disorder (PTSD). In a letter dated Aug. 9 and released by Lykos Therapeutics, the for‐profit arm of the Multidisciplinary Association for Psychedelic Studies (MAPS), the company stated that it is disappointed in the FDA response, but that it intends to pursue the goal of approval. This announcement was followed by the retraction of three peer‐reviewed studies on Aug. 9 as well. The FDA did not completely reject the idea of ever approving MDMA, but asked Lykos for more information.
- Subjects
PSYCHOTHERAPY; POST-traumatic stress disorder; HEALTH services accessibility; PATIENT safety; MEETINGS; ECSTASY (Drug); UNITED States. Food &; Drug Administration; DECISION making; DRUG efficacy
- Publication
Brown University Child & Adolescent Psychopharmacology Update, 2024, Vol 26, Issue 10, p7
- ISSN
1527-8395
- Publication type
Article
- DOI
10.1002/cpu30905